新華醫療(600587.SH):控股股東變更為國欣頤養集團
格隆匯 1 月 22日丨新華醫療(600587.SH)公佈,公司於2021年1月22日收到山東國欣頤養健康產業發展集團有限公司(“國欣頤養集團”)轉來的《中國證券登記結算有限責任公司投資者證券持有變更信息(滬市)》,確認淄博礦業集團有限責任公司(“淄礦集團”)與國欣頤養集團關於新華醫療國有股權劃轉過户手續已辦理完畢。此次劃轉完成後,淄礦集團不再持有公司股份,國欣頤養集團持有公司1.17億股股份,佔公司總股本的28.77%。
此次國有股權無償劃轉導致公司控股股東由淄礦集團變更為國欣頤養集團,公司實際控制人未發生變化,仍為山東省國有資產監督管理委員會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.